Ghanshyam Yadav, MD | Authors


Explaining Synergy in the Olaparib/Neratinib Combination for Uterine Serous Carcinomas

July 02, 2019

Ghanshyam Yadav, MD, a first-year resident in Obstetrics Gynecology & Reproductive Services, Baylor College of Medicine, talks through the results of a preclinical trial that found synergy in the combination of the PARP inhibitor olaparib and the pan-HER tyrosine kinase inhibitor neratinib for uterine serous cancers that overexpress HER2.